MA24273A1 - (4-arylthiazol-2yl) sulfonamides et leur utilisation - Google Patents

(4-arylthiazol-2yl) sulfonamides et leur utilisation

Info

Publication number
MA24273A1
MA24273A1 MA24722A MA24722A MA24273A1 MA 24273 A1 MA24273 A1 MA 24273A1 MA 24722 A MA24722 A MA 24722A MA 24722 A MA24722 A MA 24722A MA 24273 A1 MA24273 A1 MA 24273A1
Authority
MA
Morocco
Prior art keywords
arylthiazol
sulfonamides
Prior art date
Application number
MA24722A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA24273A1 publication Critical patent/MA24273A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA24722A 1996-07-19 1997-07-17 (4-arylthiazol-2yl) sulfonamides et leur utilisation MA24273A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96111661 1996-07-19

Publications (1)

Publication Number Publication Date
MA24273A1 true MA24273A1 (fr) 1998-04-01

Family

ID=8223010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24722A MA24273A1 (fr) 1996-07-19 1997-07-17 (4-arylthiazol-2yl) sulfonamides et leur utilisation

Country Status (23)

Country Link
US (2) US5877193A (fr)
EP (1) EP0819681A3 (fr)
JP (1) JP2991679B2 (fr)
KR (1) KR100247672B1 (fr)
CN (1) CN1176101A (fr)
AU (1) AU725496B2 (fr)
BR (1) BR9704023A (fr)
CA (1) CA2210613A1 (fr)
CO (1) CO4900053A1 (fr)
CZ (1) CZ227397A3 (fr)
HR (1) HRP970393A2 (fr)
HU (1) HUP9701193A3 (fr)
IL (1) IL121298A (fr)
MA (1) MA24273A1 (fr)
MX (1) MX9705385A (fr)
NO (1) NO973338L (fr)
NZ (1) NZ328331A (fr)
PE (1) PE91298A1 (fr)
PL (1) PL321203A1 (fr)
SG (1) SG91796A1 (fr)
TR (1) TR199700653A2 (fr)
YU (1) YU30297A (fr)
ZA (1) ZA976222B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725141D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Benzenesulfonamide compounds
GB9725138D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Thiophenesulfonamide compounds
US6211185B1 (en) 1999-05-05 2001-04-03 Veterinary Pharmacy Corporation Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
HUP0303857A3 (en) * 2000-12-13 2007-07-30 Wyeth Corp Heterocyclic sulifonamide inhibitors of beta amyloid production
RS44304A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
FR2849599B1 (fr) * 2003-01-07 2006-12-29 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
JPWO2005054216A1 (ja) * 2003-12-01 2007-06-28 株式会社リバース・プロテオミクス研究所 新規抗癌剤「スルコキシン」
DK2054397T3 (en) * 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2420494B1 (fr) 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Utilisation de composes derives de thiadiazoles comme inhibiteurs de la kynurenine-3- monooxygenase
EP2240023A4 (fr) * 2008-01-15 2010-12-29 Siga Technologies Inc Médicaments antiviraux pour le traitement d'une infection par un arénavirus
WO2009124086A2 (fr) * 2008-04-04 2009-10-08 Siga Technologies, Inc. Médicament antibactérien pour le traitement d’infections à staphylococcus aureus et d’autres bactéries gram positif
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN101602687A (zh) * 2008-06-13 2009-12-16 上海特化医药科技有限公司 6-硝基苯乙酮类化合物、其制备方法及用途
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
CN102633695A (zh) * 2012-04-05 2012-08-15 天津理工大学 一种4-异丙基苯磺酰氯的制备方法和工艺
CN102633687B (zh) * 2012-04-05 2016-06-08 天津瑞岭化工有限公司 一种对位取代烷基苯磺酰氯的制备方法和工艺
CN102627589A (zh) * 2012-04-05 2012-08-08 天津理工大学 一种两步合成制备4-异丙基苯磺酰氯的方法和工艺
CN102633696A (zh) * 2012-04-05 2012-08-15 天津理工大学 一种两步合成制备对位取代烷基苯磺酰氯的方法和工艺
ES2660822T3 (es) * 2012-09-21 2018-03-26 Rhode Island Hospital Inhibidores de beta-hidrolasa para tratamiento del cáncer
PL3458449T3 (pl) 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
US12030875B2 (en) * 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN114516807B (zh) * 2022-02-24 2023-11-17 南京大学 一种含硝基多取代芳香二胺单体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
AU689972B2 (en) * 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives

Also Published As

Publication number Publication date
JP2991679B2 (ja) 1999-12-20
IL121298A0 (en) 1998-01-04
KR980008228A (ko) 1998-04-30
IL121298A (en) 2001-03-19
NZ328331A (en) 1999-05-28
CA2210613A1 (fr) 1998-01-19
HUP9701193A2 (hu) 1999-02-01
US5958910A (en) 1999-09-28
MX9705385A (es) 1998-04-30
EP0819681A2 (fr) 1998-01-21
BR9704023A (pt) 1998-11-17
PL321203A1 (en) 1998-02-02
AU2875297A (en) 1998-01-29
TR199700653A2 (xx) 1998-02-21
JPH1067761A (ja) 1998-03-10
HU9701193D0 (en) 1997-09-29
AU725496B2 (en) 2000-10-12
YU30297A (sh) 2000-10-30
SG91796A1 (en) 2002-10-15
NO973338D0 (no) 1997-07-18
US5877193A (en) 1999-03-02
EP0819681A3 (fr) 1998-02-04
HUP9701193A3 (en) 2000-08-28
KR100247672B1 (ko) 2000-04-01
PE91298A1 (es) 1998-12-31
ZA976222B (en) 1998-01-19
NO973338L (no) 1998-01-20
CN1176101A (zh) 1998-03-18
HRP970393A2 (en) 1998-04-30
CZ227397A3 (cs) 1998-02-18
CO4900053A1 (es) 2000-03-27

Similar Documents

Publication Publication Date Title
MA24273A1 (fr) (4-arylthiazol-2yl) sulfonamides et leur utilisation
MA24237A1 (fr) Sulfonamides et leur utilisation.
NO984316D0 (no) Skjµreverkt°y
ID15921A (id) Peralatan pengeringan
DE69706890D1 (de) Vorausbezahlte karte
NO983462D0 (no) Isoleringsverkt°y
DE69720546D1 (de) Kaskadierter Anschluss von kommuniziernden Geräten
NO982414D0 (no) Ny kombinasjon
ID17873A (id) Penghambat trombin baru
NO990552D0 (no) Innrettingsverkt°y
EP1012279A4 (fr) Genes de mitofusine et leur utilisation
DE69724381D1 (de) Nichtreziproke Schaltungsanordnung
BR9708248A (pt) Benzotiofenos formulações contendo os mesmos e metódos
FI960994L (fi) Erotuslaite ja siinä olevia komponentteja
IS4998A (is) Flokkunarbúnaður
EP1241257A4 (fr) Polypeptides de type tachykinine et utilisation associee
EP1000925A4 (fr) Derives de triphenylmethane et leur utilisation
FR2757398B1 (fr) Formulation de bambuterol et son utilisation
FR2722198B1 (fr) 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co
ID16791A (id) Peralatan pengering
DE69736101D1 (de) Y/C-Zweizeilen-Trennvorrichtung
DE69714188D1 (de) Y/C-Trennstufe
KR980000320U (ko) 뺏지 부착용 핀
DE59703536D1 (de) Grenzwertschalter
KR950031586U (ko) 급속 및 일반 충전회로